The use of albumin in addition to crystalloids in patients with severe sepsis during early resuscitation and ICU stay to correct hypoalbuminemia does not provide survival benefit at 90 days over the use of crystalloids alone, despite improvements in hemodynamics. The clinical benefit of albumin in the subgroup of patients with septic shock deserves further confirmation, however available data suggest that, in the most severe septic shock patients, albumin supplementation should be considered.
The Albumin for Volume Replacement in Severe Sepsis (ALBIOS) Trial / L. Gattinoni. ((Intervento presentato al 44. convegno Critical Care Congress tenutosi a Phoenix nel 2015.
The Albumin for Volume Replacement in Severe Sepsis (ALBIOS) Trial
L. GattinoniPrimo
2015
Abstract
The use of albumin in addition to crystalloids in patients with severe sepsis during early resuscitation and ICU stay to correct hypoalbuminemia does not provide survival benefit at 90 days over the use of crystalloids alone, despite improvements in hemodynamics. The clinical benefit of albumin in the subgroup of patients with septic shock deserves further confirmation, however available data suggest that, in the most severe septic shock patients, albumin supplementation should be considered.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
